Psoriasis Treatment Guidelines

Introduction to Psoriasis Treatment

The American Academy of Dermatology recommends a combination of calcipotriene and betamethasone dipropionate as the best medication for treating psoriasis, providing superior efficacy compared to either agent alone with a good safety profile for up to 52 weeks 1, 2

For patients with mild to moderate psoriasis, the American Academy of Dermatology recommends topical therapy as first-line treatment, with vitamin D analogs plus corticosteroid combinations, such as calcipotriene 0.005% plus betamethasone dipropionate 0.064%, being the most effective combination with strong evidence (Grade A recommendation) 1, 2
The American Academy of Dermatology suggests that in a 52-week study, 69-74% of patients achieved clear or almost clear status with the combination of calcipotriene and betamethasone dipropionate versus 27% with vehicle control 2
For patients with moderate to severe psoriasis, the American Academy of Dermatology recommends systemic therapy, with biologics, such as TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, and IL-23 inhibitors, being strongly recommended 3, 4
The American Academy of Dermatology notes that newer biologics (IL-17, IL-23 inhibitors) show higher efficacy for skin involvement than TNF inhibitors 4

For scalp psoriasis, the American Academy of Dermatology recommends calcipotriene foam and calcipotriene plus betamethasone dipropionate gel for 4-12 weeks (Grade A recommendation) 1, 2
For facial psoriasis, the American Academy of Dermatology suggests topical tacalcitol ointment or calcipotriene combined with hydrocortisone for 8 weeks (Grade B recommendation) 1, 2
For nail psoriasis, the American Academy of Dermatology recommends topical vitamin D analogs combined with betamethasone dipropionate to reduce nail thickness, hyperkeratosis, onycholysis, and pain 5
For palmoplantar psoriasis, the American Academy of Dermatology suggests topical maxacalcitol ointment as initial treatment, and acitretin for palmoplantar pustular psoriasis 5, 6

The American Academy of Dermatology recommends combination strategies, such as vitamin D + corticosteroid regimens, with morning high-potency topical corticosteroid and evening topical vitamin D analog (Grade B recommendation) 1
The American Academy of Dermatology suggests that these regimens reduce adverse effects of topical corticosteroids and may be more cost-effective 2

The American Academy of Dermatology notes that no serious adverse events were observed over 52 weeks with calcipotriene 0.005% and betamethasone 0.064% 2
The American Academy of Dermatology recommends monitoring for specific adverse effects with systemic treatments, such as liver function with methotrexate and renal function with cyclosporine 6

The American Academy of Dermatology recommends systemic therapy with biologic agents as the first-line treatment for severe psoriasis covering the whole body (>10% body surface area), with topical therapies used as adjunctive therapy to enhance clearance and maintain remission 7, 8
Severe psoriasis patients should be under the continuing supervision of a consultant dermatologist due to the potential toxicity of systemic agents 9

The British Journal of Dermatology suggests that TNF inhibitors, such as adalimumab and infliximab, can be used as first-line systemic therapy for severe psoriasis, with 80% of patients achieving PASI 75 by week 16 8
Interrupted biologic therapy should be avoided due to increased risk of infusion reactions and poorer disease control 8

Methotrexate can be used as an alternative systemic agent, starting at 7.5 mg weekly and increasing to a maximum of 25 mg as tolerated 8
Cyclosporine can be used at a low dose (2 mg/kg/day) and is effective, but requires renal function monitoring 10

The American Academy of Dermatology recommends adding ultrahigh potency (class 1) topical corticosteroid for 12 weeks to biologics, such as etanercept and adalimumab, to accelerate clearance and target residual plaques (Grade A recommendation) 10
Calcipotriene/betamethasone dipropionate can be added to biologics to accelerate plaque clearance (Grade B recommendation) 10

The American Academy of Dermatology advises against using topical therapy alone for severe whole-body psoriasis, as this is inadequate and delays appropriate systemic treatment 7, 9
Interrupted biologic therapy should be avoided, as it increases antibody formation and reduces efficacy 8

Regular examinations are necessary to assess for skin atrophy, especially with unsupervised long-term use of topical corticosteroids 11

Significant improvement is expected with systemic therapy, with 58-92% improvement at weeks 8-16 8, 11
Re-treatment response rates are lower if adequate response is lost after stopping biologics, suggesting continuous therapy is preferable 8
Maintaining topical therapy during systemic treatment can prevent quick relapse when systemics are discontinued 12

The American Academy of Dermatology classifies betamethasone dipropionate 0.05% as Class 2 (high potency) in ointment form and Class 3-4 (mid-high potency) in cream form, while mometasone furoate 0.1% is classified as Class 4-5 (mid potency) 13, 14, 15, 16

The combination of betamethasone dipropionate and calcipotriene has synergistic effects and is more effective than either agent alone 17
Apply betamethasone dipropionate combined with calcipotriene once daily for optimal efficacy and compliance 18

To minimize long-term corticosteroid risks, use betamethasone dipropionate + calcipotriene twice daily in the initial phase, then shift to weekend-only betamethasone with 5-day/week vitamin D analog in the transition phase, and finally switch to mometasone furoate once daily or alternate-day application in the maintenance phase 17, 18

Do not assume "tachyphylaxis" - perceived treatment failure is usually due to poor adherence, not receptor down-regulation 18
Do not use high-potency agents on face/intertriginous areas when mometasone would be safer 18